search
Back to results

Degenerative Lumbar Stenosis Conservative Treatment (GOLDSTEN)

Primary Purpose

Spinal Stenosis Lumbar, Spinal Canal Stenosis

Status
Unknown status
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
Goldic serum
Steroid injections
Manual therapy
Sponsored by
Sutherland Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Stenosis Lumbar

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinical signs of lumbar spinal stenosis
  2. Radiological signs of lumbar spinal stenosis confirmed by MRI
  3. No contraindications to steroid therapy or spinal epidural injections (glaucoma, high RR values, diabetes, anticoagulants, active infections, etc.)
  4. Mental state allowing cooperation during manual therapy
  5. An adult who consents to participate in the study
  6. No previous surgery or spinal epidural injections

Exclusion Criteria:

  1. The presence of serious neurological deficits
  2. Stenosis of other origin - post-traumatic, spondylolisthesis, cancer, infection
  3. Contraindications to steroid therapy or spinal injections (glaucoma, high RR values, diabetes, anticoagulants, active infections, etc.)
  4. Previous surgery or spinal epidural injections of lumbar spine
  5. Mental state preventing cooperation during manual therapy
  6. Lack of consent to participate in the study

Sites / Locations

  • Sutherland Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

GOLDIC serum

Steroid

Manual therapy

Arm Description

Epidural ultrasound guided injections

Epidural ultrasound guided injections

veno-lymphatic spinal drainage

Outcomes

Primary Outcome Measures

Change in EQ-5D-5L index from baseline to 24 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Change in Oswestry Disability Index from baseline to 24 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 24 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).

Secondary Outcome Measures

Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Change in EQ-5D-5L index from baseline to 4 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Change in EQ-5D-5L index from baseline to 12 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Change in Oswestry Disability Index from baseline to 4 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Change in Oswestry Disability Index from baseline to 12 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 4 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 12 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).

Full Information

First Posted
July 20, 2020
Last Updated
March 10, 2021
Sponsor
Sutherland Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04492774
Brief Title
Degenerative Lumbar Stenosis Conservative Treatment
Acronym
GOLDSTEN
Official Title
GOLDIC Therapy in Lumbar Degenerative Spinal Stenosis - Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sutherland Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The trial aims to compare the effectiveness of three methods of conservative treatment of degenerative lumbar spine stenosis (DLSS): GOLDIC autologous serum epidural injections, steroid epidural injections and manual therapy.
Detailed Description
BACKGROUND: Degenerative Lumbar Spinal Stenosis (DLSS) is a serious health problem for patients over 65 years of age. It is assumed that in the United States alone, it affects about 200 thousand patients causing significant impairment of their quality of life. Although it is relatively easy to confirm the nature of spinal canal encroaching (disc protrusion, facet hypertrophy, ligamentous folding) by several methods of imaging, the golden standard of DLSS management, especially in the group of older patients, is still the matter of debate. Three main concepts of conservative treatment are considered: 1) pharmacological care - symptom-oriented systemic anty-inflammatory and analgesic agents or local steroid injections, 2) rehabilitations protocols and mechanical devices like traction facilities or corsets to decompress spinal canal or support in case of instability, 3) biological - stimulation of anti-inflammatory action and regeneration capacity by biologically active substances. All methods are offered without strong evidence of its efficacy. AIM: Comparison of the effectiveness of three treatment protocols in DLSS: epidural injections of autologous serum (Gold Induced Cytokines, Goldic), epidural steroid injections, manual therapy in the concept of spinal canal venous drainage. Research hypothesis: The use of Goldic serum in epidural injections improves the condition of patients with DLSS during the observation period longer than steroid injections and the rehabilitation protocol. DESIGN: Randomized prospective trial without blinding. SETTING: Open study for outpatients, single-centre study. POPULATION: the local adult population METHODS: Three groups of patients (A, B, C) with confirmed DLSS in MRI, without limiting sex, age, meeting health conditions according to the inclusion and exclusion criteria. There will be 30 people in each group (90 people in total). Group A - Goldic serum therapy - 4 injections at 3-day intervals containing single doses of serum (4 doses of 3 ml in total), injections performed into the epidural space under ultrasound control by the same operator. Group B - steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals containing single doses of dexamethasone (total dose of 8 mg), injections will be performed into the epidural space under ultrasound control by the same operator. Group C - manual therapy according to the concept of venous drainage - a repeatable treatment scheme for each patient; decompression of the thoracic outlet, diaphragm release, sacroiliac joints (SI) mobilizations, rib-sternum release, rib raising technique - 4 sessions (1 x weekly - approx. 40 min). Control tools: NRS Pain Scale (0-10), Oswestry Disability Index, Zurich Claudication Questionnaire (ZCQ), EQ-5D-5L, Control points: Initial Assessment (IA), 4,12, 24 weeks after last intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Stenosis Lumbar, Spinal Canal Stenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
None (Open Label)
Masking Description
None (Open label)
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GOLDIC serum
Arm Type
Experimental
Arm Description
Epidural ultrasound guided injections
Arm Title
Steroid
Arm Type
Active Comparator
Arm Description
Epidural ultrasound guided injections
Arm Title
Manual therapy
Arm Type
Active Comparator
Arm Description
veno-lymphatic spinal drainage
Intervention Type
Combination Product
Intervention Name(s)
Goldic serum
Other Intervention Name(s)
Autologous serum
Intervention Description
epidural injections
Intervention Type
Drug
Intervention Name(s)
Steroid injections
Other Intervention Name(s)
Dexamethasone
Intervention Description
epidural injections
Intervention Type
Procedure
Intervention Name(s)
Manual therapy
Other Intervention Name(s)
drainage
Intervention Description
Veno-lymphatic drainage
Primary Outcome Measure Information:
Title
Change in EQ-5D-5L index from baseline to 24 weeks
Description
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Time Frame
Change from baseline to 24 weeks
Title
Change in Oswestry Disability Index from baseline to 24 weeks
Description
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time Frame
Change from baseline to 24 weeks
Title
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 24 weeks
Description
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time Frame
Change from baseline to 24 weeks
Secondary Outcome Measure Information:
Title
Change in pain intensity according to Numeric Rating Scale
Description
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time Frame
Change from baseline to 4 weeks
Title
Change in pain intensity according to Numeric Rating Scale
Description
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time Frame
Change from baseline to 12 weeks
Title
Change in pain intensity according to Numeric Rating Scale
Description
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time Frame
Change from baseline to 24 weeks
Title
Change in EQ-5D-5L index from baseline to 4 weeks
Description
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Time Frame
Change from baseline to 4 weeks
Title
Change in EQ-5D-5L index from baseline to 12 weeks
Description
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Time Frame
Change from baseline to 12 weeks
Title
Change in Oswestry Disability Index from baseline to 4 weeks
Description
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time Frame
Change from baseline to 4 weeks
Title
Change in Oswestry Disability Index from baseline to 12 weeks
Description
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time Frame
Change from baseline to 12 weeks
Title
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 4 weeks
Description
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time Frame
Change from baseline to 4 weeks
Title
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 12 weeks
Description
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time Frame
Change from baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical signs of lumbar spinal stenosis Radiological signs of lumbar spinal stenosis confirmed by MRI No contraindications to steroid therapy or spinal epidural injections (glaucoma, high RR values, diabetes, anticoagulants, active infections, etc.) Mental state allowing cooperation during manual therapy An adult who consents to participate in the study No previous surgery or spinal epidural injections Exclusion Criteria: The presence of serious neurological deficits Stenosis of other origin - post-traumatic, spondylolisthesis, cancer, infection Contraindications to steroid therapy or spinal injections (glaucoma, high RR values, diabetes, anticoagulants, active infections, etc.) Previous surgery or spinal epidural injections of lumbar spine Mental state preventing cooperation during manual therapy Lack of consent to participate in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piotr Godek, PhD
Organizational Affiliation
Sutherland Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sutherland Medical Center
City
Warszawa
State/Province
Mazovia
ZIP/Postal Code
04-036
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35899459
Citation
Godek P, Szczepanowska-Wolowiec B, Golicki D. GOLDIC therapy in degenerative lumbar spinal stenosis: randomized, controlled trial. Regen Med. 2022 Oct;17(10):709-718. doi: 10.2217/rme-2022-0047. Epub 2022 Jul 28.
Results Reference
derived

Learn more about this trial

Degenerative Lumbar Stenosis Conservative Treatment

We'll reach out to this number within 24 hrs